Clinical Trials Browser

Malignant Ascites × Clear all

NCT07397819 2026-02-09

Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy

Phase 1/2 Recruiting

Malignant Ascites

NCT06432296 2025-07-20

Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

Phase 3 Active not recruiting

Malignant Ascites

NCT07007988 2025-06-06

SIM0388-101

Phase 1 Recruiting

Malignant Ascites

NCT06433869 2024-05-30

The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites

Phase 2 Recruiting

Malignant Ascites

NCT06200376 2024-01-11

A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer

Phase 1 Unknown

Malignant Ascites

NCT05745233 2023-08-24

Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites

Phase NA Enrolling by invitation

Malignant Ascites

NCT05501340 2022-08-15

PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites

Phase 1/2 Unknown

Malignant Ascites